Rational acyclovir therapy in herpetic eye disease

M G FALCON
From the Department of Ophthalmology, St Thomas’s Hospital, London SE1 7EH

SUMMARY Acyclovir has been widely used against the various manifestations of eye disease due to herpes simplex since it first became generally available in the UK nearly five years ago. This paper discusses the rational indications for its use, through considerations of its pharmacology and pharmacokinetics, and through results of the many clinical trials that have been carried out to investigate its effects since its clinical efficacy was first demonstrated in 1979.

Pharmacology and pharmacokinetics of acyclovir

The antiviral effect of acyclovir (ACV) was first described by Elion et al. in 1977 and subsequently by Schaeffer et al. It was the result of a systematic search for a specific antiherpex antiviral that exploits the fact that cells replicating these viruses, and particularly herpes simplex virus (HSV), are induced by the virus to produce thymidine kinase (TK). This enzyme activates ACV to the monophosphate—the first stage in the antiviral action of the drug that gives it an overall 3000 fold greater effect against HSV replication than against host cell synthesis. ACV itself is inactive, and its lack of toxicity not only allows prolonged topical therapy if necessary, but also systemic therapy—a fact that has made dramatic improvements in the management of herpes simplex virus infections in immunocompromised patients and in those with herpes simplex encephalitis. Toxicity from topical ocular therapy with idoxuridine, trifluorothymidine, and adenine arabinoside has become widely recognised.

Topical application of ACV to the eye leads to therapeutic levels in the aqueous, even when the epithelium is intact, though there have been suggestions that the stromal levels from 3% ointment may be suboptimal. Oral therapy also leads to adequate levels of ACV in tears and aqueous, for ACV crosses the blood-aqueous barrier.

It is not difficult to isolate strains of HSV that are ACV resistant: they are relatively or completely independent of TK. These strains are, however, of low virulence, and clinical problems with ACV resistance have been minor; but they could increase with increasing use of the drug.

Correspondence to MG Falcon, FRCS.

Rational use of acyclovir

PRIMARY HERPES SIMPLEX

Recent figures for the serological evidence of past (primary) herpetic infection vary between approximately 30% and 80%, but overt primary herpes occurs in only a small proportion of these individuals. By implication the condition is often very minor and self limiting, though ocular involvement may ensue, and a severe disease can occur in immunocompromised or atopic persons. Neonates can suffer a severe ocular disease from HSV types 1 or 2, with conjunctivitis, keratitis, chorioretinitis, optic neuropathy, and cataract. Herpes encephalitis and a variety of other effects on the CNS can follow primary herpetic. Transneuronal spread can occur, so that the eye can be the site of recurrence from primary herpetic elsewhere. This may also be one explanation for bilateral herpetic keratitis.

It is obviously essential to treat patients who have a serious form of primary herpes simplex. ACV is the drug of choice, since the systemic route will often be required. Topical treatment to skin lesions with IDU and even with ACV has little proved benefit, though topical treatment might be of benefit in preventing canalicular involvement, which has been shown to be a potent cause of canalicular obstruction in young people; and topical treatment is clearly indicated if involvement of the globe follows the primary disease.

PREVENTION OF LATENCY AND RECURRENT

There is no clinical evidence that treatment of primary herpetic can reduce the likelihood of latency, or recurrence, although there is experimental evidence that the early administration of ACV following HSV inoculation in the eye can reduce the...
Rational acyclovir therapy in herpetic eye disease

Evidence of latency.\textsuperscript{21} It is certainly the case that no means are yet available to eradicate latency once it has occurred. The presence of latent virus (of a particular strain) in the ganglion seems both to determine the clinical characteristics of the disease (in the eye)\textsuperscript{22,23} and to inhibit the entry of virus of a different strain, although this latter effect is incomplete.\textsuperscript{24} Evidence is also accumulating that the cornea (and perhaps other peripheral sites) may be the site of a 'latent' viral phase from which virus can be cultured\textsuperscript{25} and seen to undergo replication in kerocytes.\textsuperscript{26} None of these new data on latency offer any further direct hope of controlling it pharmacologically (if this is, indeed, desirable). In the meantime there is the possibility of long term prophylaxis with antiviral therapy. Obvious risks are the development of toxicity, and the development of resistant strains of HSV. No firm clinical data are available (apart from the special case where steroids provide the risk factor—considered elsewhere), but it is probably best to avoid long term prophylaxis, and to reserve short term prophylaxis for those individuals who can recognise trigger factors, using prophylaxis at these appropriate times. Experimentally, local or systemic ACV will prevent recurrences if it is given before the trigger factor appears.\textsuperscript{27}

**Herpetic Conjunctivitis**

HSV is a common cause of conjunctivitis.\textsuperscript{13} It is often self limiting, though it can sometimes lead on to a keratitis resembling that due to adenovirus types 8 or 19, and it represents one part of the spectrum, ranging from an absence of symptoms or signs, to frank herpetic keratitis, that can result from repeated virus shedding. Since the outcome is uncertain when these patients are first seen, and since laboratory diagnosis is often not proved, it could be reasonably argued that antiviral therapy is appropriate, but there are no grounds for favouring any particular drug.

**Ulcerative Herpetic Keratitis**

The clinical trial that first showed that topical ACV was effective against dendritic ulcers was constructed in such a way that a minimum quantity of the drug was used.\textsuperscript{28} A large number of trials have since been carried out comparing ACV with IDU, Ara-A and F3T in patients with dendritic ulcers—using this very convenient microsystem to provide precise information on healing rates, healing percentages, toxicity, subsequent deep disease, and other complications. It may seem somewhat surprising that there has not been complete agreement in the results, though comparisons across different clinical trials are notoriously insecure. The trials of Coster et al.\textsuperscript{29} and Collum et al.\textsuperscript{30} are noteworthy in this regard: the first found no difference between ACV and IDU, whereas the second found ACV to be superior. The most cautious conclusion overall is perhaps that for patients with dendritic ulcers, which represent a simple task for the antiviral agent, no antiviral has been repeatedly demonstrated to be superior to any other. It could be argued that IDU should be used initially because it is effective and inexpensive and ACV should be reserved for possible future events such as disciform keratitis, where its particular advantages will be realised, or for circumstances where oral therapy is preferably to local,\textsuperscript{31} ACV being effective by either route.\textsuperscript{9} As already indicated, the primary use of ACV would be likely to select for ACV resistant strains of HSV, although these have not been a problem in clinical practice, perhaps because these strains are of low virulence.

Amoeboid ulcers present a more challenging problem for an antiviral than do dendrites, and their prognosis is worse in every way.\textsuperscript{32} Clinical trials demonstrated a superiority of F3T over Ara-A,\textsuperscript{33} but ACV and Ara-A were recently shown to have equivalent effects.\textsuperscript{34} Probably an important issue is the entry of the antiviral into the stroma, which will occur with F3T when the epithelium is breached and with ACV even when it is intact, since there may be replicating stromal virus in these patients. Either drug is thus preferable to IDU or Ara-A. However, F3T is not readily available in the UK, whereas it is marketed in the USA, but ACV is not.

Indolent ('metaherpetic') ulcers are perpetuated by such factors as antiviral toxicity, loss of corneal sensation, damage to basement membrane, stromal disease, and tear film inadequacy; and, by definition, viral replication is not occurring in the epithelium. This is not always the case in the stroma,\textsuperscript{35} but even if the stromal disease is not being caused by viral replication, there may be a need for antiviral therapy to 'cover' steroid therapy. It seems reasonable to suggest that ACV should be the antiviral of choice in these patients: firstly, because it is the least toxic antiviral, and secondly because it has good ocular penetration.

**Keratouveitis**

Numerous experimental and clinical studies have shown that deep keratitis and/or uveitis can be caused by viral replication or various immune mechanisms, and it is probably safest for the clinician to consider that both mechanisms are usually occurring, though to differing degrees in different patients, with the various forms of herpetic keratouveitis. Oh\textsuperscript{36} has produced evidence that viral replication may occur in primary HSV uveitis but not recurrent disease (the latter being commoner clinically). But viral replication may undoubtedly be triggered off by steroid therapy,\textsuperscript{37} both in the epithelium and in the stroma.
and the use of a penetrating antiviral during steroid therapy for stromal disease appears logical.

Both steroids and ACV have been useful investigative tools in HSV keratoconjunctivitis. Cullum and colleagues’ demonstration of the benefit from ACV and betamethasone compared with ACV alone in patients with disciform keratitis was the first trial to prove the short term value of steroids in this disease—a benefit nevertheless little doubted—and Colin et al. found that ACV was superior to F1T or Ara-A when used in combination with steroids for patients with deep disease. Sundmacher has conversely shown a benefit from oral ACV in patients with virologically proved intraocular HSV disease, and Wilhelmus et al. obtained a probable benefit from topical ACV compared with IDU in patients with herpetic uveitis. van Ganswijk et al. found resolution of stromal keratitis within four weeks of starting ACV therapy in 35 patients with refractory deep disease, but Sanitato et al. found no benefit from ACV in the management of 17 patients with herpetic stromal disease. Maudgal et al. obtained good effects from a water soluble derivative of ACV (applied as drops) in the treatment of experimental keratitis produced by intrastromal injection of live virus. Maudgal’s group found F1T to be superior to 3% ACV ointment in this model, and suggested that a higher dosage of ACV than 3% ointment five times a day might be required for optimal stromal levels.

From these considerations it would appear logical to treat patients with HSV keratoconjunctivitis firstly with a penetrating antiviral alone, or even to use oral therapy for HSV uveitis, and to add as little steroid as possible if there is an inadequate response to the former. In the UK ACV is the drug of choice, and its lack of toxicity makes it particularly suitable for the long term therapy that is needed to accompany long term steroid therapy.

**POSTERIOR SEGMENT DISEASE**

Evidence is accumulating, particularly from vitreous specimens and retinal biopsy, that acute retinal necrosis and choroidoretinitis can sometimes be caused by HSV. Grutzmacher et al. treated one such patient (virologically proved) with ACV successfully.

The safety of ACV for intravitreal as well as oral use is particularly attractive. It may have a role in cytomegalovirus retinitis, though the in-vitro efficacy against CMV is not as strong as against HSV. Hydroxy ACV may prove to be superior.

**KERATOPLASTY**

There has for some years been considerable discussion about the value (or otherwise) of using long term prophylactic antiviral therapy following grafting for herpes. Much of the earlier work inevitably referred only to IDU, and it was demonstrated that the risk of toxicity from this drug on the epithelium of the graft was unacceptably high. However, Cobo et al. showed that recurrence of herpetic epithelial disease was particularly likely in patients who developed a recurrence of inflammatory disease (whether due to rejection or herpes) following keratoplasty, and this emphasised the need to cover the appropriately intensive steroid therapy that was given at this time. ACV (or perhaps F1T, if available, and if not used for too long) would be the drug of choice for reasons already mentioned.

But what of long term ACV prophylaxis following grafting? It is certainly safe, but it may be undesirable to give ACV for many months (the incidence of recurrence remaining high for over a year postoperatively). It was shown by Kok van Alphen and Volker-Dieben in a relatively small study that prophylaxis with ACV during the first months after operation did not appear to reduce the risk of recurrence. Probably the wisest action to take in the light of present knowledge is to give ACV prophylaxis to those patients deemed to be at a particular high risk of recurrence, such as those requiring a high level of steroid, or those receiving a graft for therapeutic reasons (in an inflamed eye); and to give ACV prophylaxis as appropriate for later episodes of inflammatory disease; but to avoid long term ACV prophylaxis for patients in relatively low risk circumstances.

**Conclusion**

An attempt has been made in this article, by drawing on the appropriate data from the numerous workers, both clinical and non-clinical, involved in herpetic keratitis to guide the clinician in the rational use of acyclovir. It is no accident that so much of the data originated either from Barrie Jones’s department or from those whose interest in herpetic eye disease was inspired by him. Acyclovir has already made a major contribution to patients suffering from this complex disease. Future developments are likely to include combination therapy—either with interferon, which has been shown to be more effective than ACV alone, or a combination with antiviral drugs such as Ara-A that work at other sites, or ACV analogues that may offer advantages over the parent compound.

I am indebted to Mrs Julie Lawrence, who typed the manuscript.

**References**

Rational acyclovir therapy in herpetic eye disease


